GTC Taps Houston's Cancer Hub for National Genomics Expansion

HOUSTON, TX – March 12, 2026 – Genomic Testing Cooperative (GTC) today announced the launch of a new 6,900-square-foot laboratory in Houston, a significant expansion that anchors the California-based company in one of the world's most formidable oncology research and treatment centers. The move is designed to enhance the company's national network for advanced cancer diagnostics, improve service for clinicians, and accelerate its mission to broaden access to precision medicine.

A Strategic Return to a Global Oncology Hub

The choice of Houston is no coincidence. The city is home to the Texas Medical Center (TMC), the largest medical complex in the world, which functions as a global epicenter for clinical innovation. With a staggering GDP of $25 billion and over 120,000 employees, the TMC ecosystem includes titans of cancer care like The University of Texas MD Anderson Cancer Center and Baylor College of Medicine. By planting a flag here, GTC positions itself at the heart of a collaborative environment that sees nearly 10 million patient encounters annually and hosts one of the largest cancer clinical trial programs on the planet.

For GTC's founder and CEO, Dr. Maher Albitar, the expansion represents a homecoming. "Houston is one of the most important centers for oncology research and care in the world," he stated. Dr. Albitar began his molecular diagnostics career in the city and spent over a decade, from 1991 to 2003, in various high-level faculty and leadership positions at MD Anderson, including Section Chief of Leukemia and Director of the molecular laboratory. His deep familiarity with the Houston medical landscape provides a unique strategic advantage.

"Returning to this ecosystem is both professionally meaningful and strategically important," Dr. Albitar added. "By establishing a laboratory here, we can collaborate more closely with leading physicians and scientists while improving turnaround times, expanding national capacity and increasing access to high-quality genomic testing for clinicians and patients across the country." This proximity is expected to foster deeper partnerships and integrate GTC's capabilities directly with the researchers and doctors on the front lines of cancer treatment.

Democratizing Diagnostics with a Cooperative Model

What sets GTC apart in a crowded field is its unique "cooperative model," a business strategy aimed at democratizing access to the sophisticated and often costly world of next-generation sequencing (NGS). Unlike traditional laboratory networks that operate in a purely competitive framework, GTC partners with other laboratories, hospitals, and healthcare systems, effectively sharing its advanced infrastructure, bioinformatics, and expertise.

This model operates on a flexible, two-tiered strategy. For smaller labs lacking the capital for expensive sequencing instruments, GTC can perform the complex DNA and RNA sequencing at its own CLIA-certified facilities, like the new one in Houston. For larger institutions that wish to build their own capabilities, GTC can assist in establishing an in-house lab, providing the crucial backend support of data analysis and interpretation through its proprietary AI and deep-learning algorithms.

The goal is to empower these partners to internalize and offer high-quality molecular testing that they might otherwise be unable to provide. By creating a network of collaborators rather than just customers, GTC aims to lower the overall cost of sequencing through shared volume and reduced overhead. This approach directly supports the company’s mission to make precision medicine a standard of care available to more communities, not just those near major academic medical centers.

Faster Answers, Broader Access for Patients

For cancer patients and their oncologists, the speed and accessibility of genomic test results can be life-altering. The detailed molecular blueprint of a tumor provided by NGS is critical for identifying targeted therapies and immunotherapies that can offer better outcomes than traditional chemotherapy. Delays in this information can mean delays in starting the most effective treatment.

GTC's Houston facility is poised to directly address this challenge. Its central location strengthens the company’s national logistics, promising to reduce sample shipping times and improve overall turnaround for diagnostic reports. The company already aims for a consistent delivery of results in ten days or less, and the new lab adds both capacity and redundancy to its network, ensuring operational continuity and faster service for customers across the United States.

Beyond speed, the expansion reinforces GTC’s commitment to tackling disparities in healthcare access. Advanced genomic testing is often concentrated in major urban and academic centers, leaving patients in rural or underserved communities at a disadvantage. By enabling regional and local labs through its cooperative model, GTC helps bring this critical technology closer to home for more patients. The company has also established programs specifically designed to offer molecular profiling to minority patients who lack adequate insurance, a direct effort to bridge the access gap and ensure more equitable entry into the era of precision oncology.

Navigating a Competitive Precision Medicine Market

GTC's expansion comes at a time of explosive growth in the genomics in cancer care market, which is projected to soar from roughly $24 billion in 2025 to over $108 billion by 2035. The company enters a dynamic and competitive landscape populated by established giants like Illumina and Thermo Fisher Scientific, as well as specialized molecular information firms such as Foundation Medicine and Caris Life Sciences.

In this environment, GTC's cooperative business model and its comprehensive approach to profiling serve as powerful differentiators. While many competitors offer similar testing services, GTC's strategy of collaboration rather than direct competition allows it to penetrate markets that others may overlook. By empowering smaller institutions, it creates a distributed network that expands its reach and builds loyalty.

Furthermore, the company's emphasis on integrated DNA and RNA sequencing provides a more complete picture of a tumor's biology, analyzing not just gene mutations but also fusions, gene expression, and alternative splicing. This depth of analysis is increasingly vital for guiding complex treatment decisions. The new Houston laboratory, situated within a nexus of clinical innovation, provides GTC with a strategic foothold to not only compete but also contribute to the next wave of discoveries in personalized cancer treatment.